Pharma 4.0 Market Size, Share & Trends Analysis Report
The global pharma 4.0 market size is expected to reach USD 35.79 billion by 2030, registering a CAGR of 18.96% from 2024 to 2030, according to a new report by Grand View Research, Inc.
世界のファーマ4.0市場規模は 2030 年までに 357 億 9,000 万米ドルに達すると予想されており、2024 年から 2030 年にかけて 18.96% の CAGR を記録します。
The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.
Pharma 4.0 Market Report Scope
| Report Attribute | Details |
| The market size value in 2024 | USD 12.62 billion |
| The revenue forecast in 2030 | USD 35.79 billion |
| Growth rate | CAGR of 18.96% from 2024 to 2030 |
| Actual data | 2018 – 2023 |
| Forecast period | 2024 – 2030 |
| Quantitative units | Revenue in USD billion & CAGR from 2024 to 2030 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Type, technology, end-use , application |
| Regions covered | North America; Europe; Asia Pacific; Latin America; MEA |
| Country Scope | U.S.; Canada; UK; Germany; France; Spain; Italy; Norway; Sweden; Denmark; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key companies profiled | Microsoft Corporation; IBM; Amazon Web Service (AWS); SAP; Oracle; GE Healthcare; Siemens Healthineers; Cisco; Cinntra; Dassault Systems; Nexocode |
| Customization scope | Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |